Beyondspring Stock News

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BeyondSpring, Inc. (NASDAQ: BYSI) for potential securities law violations. Investors who have lost money in their BeyondSpring investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bysi .

Charles Schwab Investment Management Inc. raised its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 17.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,461 shares of the companys stock after acquiring an additional 6,915 shares during the quarter. Charles Schwab Investment Management Inc. []

HC Wainwright downgraded shares of BeyondSpring (NASDAQ:BYSI) from a buy rating to a neutral rating in a report published on Wednesday, Analyst Price Targets reports. Several other research firms also recently weighed in on BYSI. Evercore ISI reissued a buy rating on shares of BeyondSpring in a report on Thursday, August 19th. William Blair reissued []

The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc''s (NASDAQ: BYSI ) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN). The application covers plinabulin in combination with granulocyte colony-stimulating factor (G-CSF). Related:

BeyondSpring Inc (NASDAQ: BYSI) is trading significantly lower Wednesday after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for

The stock price of BeyondSpring Inc (NASDAQ: BYSI) fell by over 55% during intraday trading today. This is why it happened.

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form.

The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc's (NASDAQ: BYSI) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia

BeyondSpring Inc. BYSI, -1.84% said Wednesday that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration, saying the biopharmaceutical company's new drug applicat

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link….

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-Operative Administration Cumber

Shares of BeyondSpring Inc. (NASDAQ:BYSI) have earned a consensus recommendation of Buy from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that []

BeyondSpring Inc. (NASDAQ:BYSI) has a beta value of 1.01 and has seen 1.48 million shares traded in the last trading session. The company, currently valued at $564.24M, closed the last trade at $14.35 per share which meant it gained $1.07 on the day or 8.06% during that session. The BYSI stock price is -129.97% off BeyondSpring Inc. (BYSI) Shares Are Up 31.77% So Far This Year Read More »

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-s